Status:
COMPLETED
Comparison Of Two Tablet Formulations Of SB-568859
Lead Sponsor:
GlaxoSmithKline
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
SB-568859 is a medication that is being developed for the treatment of atherosclerosis (hardening of the arteries). The purpose of this study is to see if there is a difference in how the human body t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy men and sterile women between 18 and 50 years old
- Body weight greater than 50 pounds and a body mass index between 19 and 31
- Normal electrocardiogram
- Exclusion criteria:
- No history of asthma or severe allergic reactions
- No history of or current drug use
- No Hepatitis or HIV/AIDS
- No excessive alcohol use
- No smoking or tobacco use
- No use of prescription drugs, over-the-counter drugs or vitamins within 7 days
- No use of herbal supplements within 14 days
- No treatment with an investigational drug within 30 days.
- No treatment with 4 or more investigational drugs in the last 12 months
- No grapefruit or grapefruit juice in the last 7 days
- No donation of blood in the last 8 weeks
- No history of allergy to heparin
- No history of liver or gall bladder disease
- Unwillingness to use contraception
Exclusion
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00470145
Start Date
April 1 2007
End Date
July 1 2007
Last Update
June 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Buffalo, New York, United States, 14202